Staff Profile

Dr. Jeyakumar S.M

Designation: Scientist F

Division/Unit: Clinical Pharmacology

Email: jeyakumar[dot]sm[at]icmr[dot]gov[dot]in

Educational Qualification

M.Sc., M.Phil., Ph.D.

Personal Statement

We are currently involved in research on how anti-tuberculosis (anti-TB) drugs are processed in the body (pharmacokinetics) and how their levels can be monitored during treatment, by using and/or developing novel HPLC and LC-MS/MS methods. Our work also includes testing anti-TB drugs in pharmaceutical formulations. In addition, we study how host and dietary factors can affect drug levels, treatment response, and overall outcomes in patients with pulmonary tuberculosis.

Research Focus

• Pharmacokinetics

• Anti-TB drug metabolism

• Drug-Drug Interaction

• Nutrition and Drug metabolism

Ongoing projects as Principal investigator

• Bioavailability of first-line anti-TB drugs among patients receiving fixed-dose combination (FDC) tablets
• Pharmacokinetics of linezolid in MDR-TB patients

Significant Publications

1. Agibothu Kupparam HK, Shah I, Chandrasekaran P, et al. Pharmacokinetics of anti-TB drugs in children and adolescents with drug-resistant TB: a multicentre observational study from India. J Antimicrob Chemother. 2024;79(11):2939-2947. doi:10.1093/jac/dkae311

2. Vilvamani S, Mahalingam S, Nhavilthodi S, Murugesan D, Jeyakumar SM. Development and Validation of a Simple High-Pressure Liquid Chromatography-Ultraviolet Detection Method for Simultaneous Quantitation of First-Line Anti-Tuberculosis Drugs in Formulations of Fixed-Dose Combination. J Chromatogr Sci. 2024;62(9):821-828. doi:10.1093/chromsci/bmae023

3. Jeyakumar SM, Bhui NK, Singla N, et al. Long-Term Intake of Linezolid Elevates Drug Exposure and Reduces Drug Clearance and Elimination in Adults With Drug-Resistant Pulmonary Tuberculosis. Ther Drug Monit. 2023;45(6):754-759. doi:10.1097/FTD.0000000000001111

4. Padmapriyadarsini C, Solanki R, Jeyakumar SM, et al. Linezolid Pharmacokinetics and Its Association with Adverse Drug Reactions in Patients with Drug-Resistant Pulmonary Tuberculosis. Antibiotics (Basel). 2023;12(4):714. Published 2023 Apr 6. doi:10.3390/antibiotics12040714

5. Jeyakumar SM. Micronutrient Deficiency in Pulmonary Tuberculosis - Perspective on Hepatic Drug Metabolism and Pharmacokinetic Variability of First-line Anti-Tuberculosis Drugs: Special Reference to Fat-soluble Vitamins A, D, & E and Nutri-epigenetics. Drug Metab Lett. 2021;14(3):166-176. doi:10.2174/1872312814999211130093625